Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a strong contender in the race to develop an effective treatment for COVID-19, with promising results in clinical trials and FDA support for their lead product PEMGARDA. The company's focus on monoclonal antibody therapies for viral infectious diseases sets them apart in an increasingly competitive market, but there are potential challenges and risks that should be carefully considered. Overall, Invivyd's dedication to research and development and potential for success make it a promising investment opportunity in the biopharmaceutical industry.

Bears say

Invivyd is facing intense competition in the biopharmaceutical industry, particularly in the field of monoclonal antibodies for COVID-19. While their lead product, PEMGARDA, received FDA emergency use authorization, there are concerns about the effectiveness of the product in the face of new variants like Omicron. Additionally, their pipeline is still in early stages of development, leaving them vulnerable to setbacks and delays.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.